Narges Mardi

524 citations
16 papers · 408 indexed · h-index 10
Topics
Extracellular vesicles in disease (11 papers)MicroRNA in disease regulation (4 papers)Barrier Structure and Function Studies (2 papers)
Partner nations
IranTürkiye

In The Last Decade

Narges Mardi

15 papers receiving 402 citations

Peers

Narges Mardi
Comparison fields: 5 of 80
  • Molecular Biology 322
  • Cancer Research 144
  • Biomedical Engineering 59
  • Immunology 42
  • Biomaterials 39
Replace Luke van der Koog with:
Luke van der Koog Netherlands
Yangxue Yao China
Lexiang Li China
Jun Gu China
Chenyuan Huang Singapore
Tahereh Etemadi Iran
Song-pei Li China
Ayelet Shabtay‐Orbach Israel
Mohamad Eftekhary Iran
Rahim Asghari Iran
Narges Mardi relative to Luke van der Koog Netherlands Luke van der Koog's profile →
Citations per field
00.5×1.5×1.9×
Luke van der Koog · 1×
Citations per year

Countries citing papers authored by Narges Mardi

Since Specialization
Citations

This map shows the geographic impact of Narges Mardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narges Mardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narges Mardi more than expected).

Fields of papers citing papers by Narges Mardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narges Mardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narges Mardi. The network helps show where Narges Mardi may publish in the future.

Co-authorship network of co-authors of Narges Mardi

This figure shows the co-authorship network connecting the top 25 collaborators of Narges Mardi. A scholar is included among the top collaborators of Narges Mardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narges Mardi. Narges Mardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
#WorkIndexed citations
1 2
2 0
3 8
4 4
5 7
6 9
7 11
8 36
9 14
10 10
11 24
12 20
13 17
14 27
15 196
16 23

About Narges Mardi

Narges Mardi is a scholar working on Cancer Research, Neurology and Biomaterials, having authored 16 papers that have together received 408 indexed citations. Recurring topics across this work include Extracellular vesicles in disease (11 papers), MicroRNA in disease regulation (4 papers) and Barrier Structure and Function Studies (2 papers). The work is most often cited by research in Cancer Research (144 citations), Molecular Biology (322 citations) and Pharmaceutical Science (22 citations). Narges Mardi has collaborated with scholars based in Iran and Türkiye. Frequent co-authors include Fatemeh Ganji, Hosna Gomari, Alí Samadikuchaksaraei, Davod Jafari, Rasool Jafari, Mehdi Forouzandeh Moghadam, Reza Rahbarghazi‬, Amir Zarebkohan, Halimeh Mobarak and Faramarz Mehrnejad. Their work appears in journals such as Cancer Letters, International Journal of Biological Macromolecules and Stem Cell Research & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026